Skip to main content
Clinical Trials/NCT05223764
NCT05223764CompletedNot Applicable

Why Are They Not Coming Back? A Single-center Follow-up Study in Fertility Preservation in Oncological Women.

Istituto Clinico Humanitas1 site in 1 country172 target enrollmentStarted: June 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
172
Locations
1
Primary Endpoint
return rate

Study Overview

Brief Summary

This is a single-center retrospective study carried out with a phone call follow-up to investigate women's decision not to return for criopreserved ovocytes use after cancer treatment. The study database includes all women who underwent fertility preservation cycles at a third-level university-affiliated center from January 2001 to December 2017.

Patients were asked a set of standardized questions whose purpose was to investigate their present health conditions, cancer treatment and any potential relapses, their family projects and sentimental status, any spontaneous conception, and why they had not yet returned for embryo transfer.

All data were recorded anonymously in our dataset.

Detailed Description

All women who underwent oocyte cryopreservation cycles for oncological purposes from January 2001 to December 2017 at Fertility Center of Humanitas Research Hospital, Rozzano (Milano), Italy, were contacted.

The survey's purpose was to investigate their present health conditions, cancer treatment and any potential relapses, their family projects and sentimental status, any spontaneous conception, and why they had not yet returned for oocytes use.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The study database includes all women who underwent fertility preservation cycles at a third-level university-affiliated center

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

return rate

Time Frame: from January 2001 to December 2021

return rate of cancer patients who underwent fertility preservation

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Istituto Clinico Humanitas
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
A descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapseNervous System DiseasesMultiple SclerosisMultiple sclerosis
ISRCTN66678006ovartis Pharmaceuticals Ltd (UK)150
Completed
Not Applicable
A multicenter, observational study for reactivation of hepatitis B virus by means of serial HBV-DNA monitoring during and just after systemic chemotherapy containing rituximab plus steroid for malignant lymphoma (C-SHOT 0802)ntreated CD20-positive, B-cell non-Hodgkin's lymphoma in the patients with seronegativity for HBsAg and seropositivity for HBc-Ab and/or HBs-Ab, which is planned to be treated with 6-8 courses of systemic chemotherapy containing rituximab plus steroid such as R-CHOP, R-CVP, R-THP-COP and R-C-MOPP
JPRN-UMIN000001299agoya City University Hospital321
Completed
Not Applicable
Retrospective, Single-Centre Data Collection Study of the Effectiveness and Safety of a Specially Designed Ductus Arteriosus Self-Expanding Stent (Sinus-SuperFlex-DS, SSF) in the Giessen Hybrid” ApproachQ23.4Hypoplastic left heart syndrome
DRKS00025766optimed Medizinische Instrumente GmbH51
Completed
Not Applicable
Multicenter Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer; the HGCSG1503 StudyColorectal Cancer
JPRN-UMIN000020551Hokkaido Gastrointestinal Cancer Study Group300
Completed
Not Applicable
Study of telemedicine in prescribing low dose pills for dysmenorrhea patientsdysmenorrhea
JPRN-UMIN000046405Yokohama City University172